인쇄하기
취소

Celltrion’s biosimilar ‘Herzuma’ proven in equivalence of efficacy with original

Published: 2017-09-13 11:04:15
Updated: 2017-09-13 11:04:15

At the European Society for Medical Oncology(ESMO) symposium on the 9th(local time) in Madrid, Spain, Celltrion announced additional clinical trial results of 1-year safety of Herzuma(development name: CT-P6), an antibody biosimilar for the treatment of breast cancer, on early breast cancer patients.

Herzuma, an antibody biosimilar used to treat breast cancer and stomach cancer, references ‘He...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.